Background/aim: The aim of the current study was to determine the effects of the ERG small-molecule inhibitor YK-4-279 on ERG prostate cancer patient-derived xenografts (PDX).
Materials And Methods: ERG activity was blocked using YK-4-279 in three subcutaneously-implanted ERG (LuCaP 23.1, 86.2 and 35) and one ERG (LuCaP 96) PDX. Treated animals tumor volume (TV), body weight (BW) and serum prostate-specific antigen (PSA) were compared to vehicle-treated control animals. Gene expression, proliferation, apoptosis, microvessel density and ERG expression were also assessed.
Results: Administration of YK-4-279 decreased TV (p=0.026), proliferation (p=0.0038) and PSA (p=0.022) in Severe Combined Immunodeficiency (SCID) mice bearing LuCaP 23.1 tumors. LuCaP 86.2, LuCaP 35 and LuCaP 96 showed no significant changes in TV, or PSA. Mineralocorticoid receptor (MR) and MR-direct target genes were up-regulated in treatment-resistant LuCaP 86.2 and LuCaP 35 PDX.
Conclusion: YK-4-279 decreased ERG LuCaP 23.1 tumor growth, but not LuCaP 86.2 and LuCaP 35 ERG tumor growth.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.21873/anticanres.11705 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Inhibition of ERG Activity in Patient-derived Prostate Cancer Xenografts by YK-4-279.
Anticancer Res
July 2017
Department of Urology, University of Washington, Seattle, WA, U.S.A.
Background/aim: The aim of the current study was to determine the effects of the ERG small-molecule inhibitor YK-4-279 on ERG prostate cancer patient-derived xenografts (PDX).
Materials And Methods: ERG activity was blocked using YK-4-279 in three subcutaneously-implanted ERG (LuCaP 23.1, 86.
LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer Therapeutics.
Prostate
May 2017
Department of Urology, University of Washington, Seattle, Washington.
Background: Metastatic prostate cancer is a common and lethal disease for which there are no therapies that produce cures or long-term durable remissions. Clinically relevant preclinical models are needed to increase our understanding of biology of this malignancy and to evaluate new agents that might provide effective treatment. Our objective was to establish and characterize patient-derived xenografts (PDXs) from advanced prostate cancer (PC) for investigation of biology and evaluation of new treatment modalities.
View Article and Find Full Text PDFCharacterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer.
Prostate
June 2016
Department of Urology, University of Washington, Seattle, Washington.
Background: The TMPRSS2-ERG gene fusion is detected in approximately half of primary prostate cancers (PCa) yet the prognostic significance remains unclear. We hypothesized that ERG promotes the expression of common genes in primary PCa and metastatic castration-resistant PCa (CRPC), with the objective of identifying ERG-associated pathways, which may promote the transition from primary PCa to CRPC.
Methods: We constructed tissue microarrays (TMA) from 127 radical prostatectomy specimens, 20 LuCaP patient-derived xenografts (PDX), and 152 CRPC metastases obtained immediately at time of death.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!